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Pulmonary arterial hypertension (PAH) has a multifactorial pathobiology. Vasoconstriction,
remodeling of the pulmonary vessel wall, and thrombosis contribute to increased pulmonary
vascular resistance in PAH. The process of pulmonary vascular remodeling involves all layers
of the vessel wall and is complicated by cellular heterogeneity within each compartment of the
pulmonary arterial wall. Indeed, each cell type (endothelial, smooth muscle, and fibroblast),
as well as inflammatory cells and platelets, may play a significant role in PAH. Pulmonary
vasoconstriction is believed to be an early component of the pulmonary hypertensive process.
Excessive vasoconstriction has been related to abnormal function or expression of potassium
channels and to endothelial dysfunction. Endothelial dysfunction leads to chronically
impaired production of vasodilators such as nitric oxide and prostacyclin along with
overexpression of vasoconstrictors such as endothelin (ET)-1. Many of these abnormalities
not only elevate vascular tone and promote vascular remodeling but also represent logical
pharmacological targets. Recent genetic and pathophysiologic studies have emphasized the
relevance of several mediators in this condition, including prostacyclin, nitric oxide, ET-1,
angiopoietin-1, serotonin, cytokines, chemokines, and members of the transforming-growth-
factor-beta superfamily. Disordered proteolysis of the extracellular matrix is also evident in
PAH. Future studies are required to find which if any of these abnormalities initiates PAH
and which ones are best targeted to cure the disease. (J Am Coll Cardiol 2004;43:13S–24S)
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ihe pulmonary circulation is a low-pressure, high-flow
ystem with a great capacity for recruitment of normally
nperfused vessels. As a consequence, the walls of pulmo-
ary arteries are thin, in keeping with their low transmural
ressure. Pulmonary arterial hypertension (PAH) is a dis-
ase of the small pulmonary arteries, characterized by
ascular narrowing leading to a progressive increase in
ulmonary vascular resistance. The consequence of this
ncreased right ventricle afterload is the failure of the
fterload-intolerant right ventricle.
Vasoconstriction, remodeling of the pulmonary vessel
all, and thrombosis contribute to the increased pulmonary
ascular resistance in PAH (1). However, it is now recog-
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iferation and remodeling is the hallmark of PAH patho-
enesis (2). The process of pulmonary vascular remodeling
nvolves all layers of the vessel wall and is complicated by the
nding that cellular heterogeneity exists within the com-
artment of the pulmonary arterial wall (2).
ELLULAR CHANGES
mooth muscle cells and fibroblasts. Each cell type (en-
othelial, smooth muscle, and fibroblast) in the pulmonary
ascular wall plays a specific role in the response to injury
2). A feature common to all forms of PAH remodeling is
he distal extension of smooth muscle into small peripheral,
ormally nonmuscular, pulmonary arteries within the respi-
atory acinus. The cellular processes underlying muscular-
zation of this distal part of the pulmonary arterial tree are
ncompletely understood. In addition, a hallmark of severe
ulmonary hypertension is the formation of a layer of
yofibroblasts and extracellular matrix between the endo-
helium and the internal elastic lamina, termed the neoin-
ima. In some model systems, particularly in hypoxia mod-
ls, the adventitial fibroblast appears to be the first cell
ctivated to proliferate and to synthesize matrix proteins in
esponse to the pulmonary hypertensive stimulus (3). The
echanisms that enable the adventitial fibroblast to migrate
nto the media (and ultimately the intima) are currently
nclear, but there is good evidence to suggest that upregu-
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Pathobiology of Pulmonary Arterial Hypertension June 16, 2004:13S–24Sation of matrix metalloproteinases (MMP2 and MMP9)
ccurs and that these molecules are involved in migration.
In many forms of pulmonary hypertension, as the vessel
all thickens, a concomitant increase occurs in neovascu-
arization of the vasa vasorum. This neovascularization
ccurs primarily in the adventitia, although it extends into
he outer parts of the media. This adventitial vessel forma-
ion could provide a conduit for circulating progenitor cells
o access the vessel wall from the adventitial side. It is
nknown whether circulating progenitor cells derived from
he bone marrow contribute directly to the adventitial
hickening and perhaps medial thickening, or whether bone
arrow-derived progenitor cells simply enhance the prolif-
rative and migratory activity of the local adventitial fibro-
lasts. Significant attention in the future will have to be
ocused on the role of circulating precursor cells to vascular
emodeling (4). In addition, evidence shows that PAH may
e associated with alterations of both rates of proliferation
nd apoptosis, which, in balance, result in thickened,
bstructive pulmonary arteries.
ndothelial cells. Disorganized endothelial cell prolifera-
ion leading to formation of plexiform lesions is described in
any cases of PAH (1,5). The initiating stimulus or injury
hat results in abnormal endothelial proliferation is un-
nown, but may include hypoxia, shear stress, inflammation,
r response to drugs or toxins on a background of genetic
usceptibility.
However, although many animal models of pulmonary
ypertension exist, none recapitulate the histology of PAH,
articularly the presence of plexiform lesions. Endothelial
ells may respond to injury in various ways affecting the
rocess of vascular remodeling. Injury can alter not only cell
roliferation and apoptosis but also homeostatic functions
f the endothelium (including coagulation pathways, and
roduction of growth factors and vasoactive agents). The
ells comprising plexiform lesions are endothelial channels
upported by a stroma containing matrix proteins and
yofibroblasts. Endothelial cells express markers of angio-
enesis, such as vascular endothelial growth factor (VEGF)
nd its receptors (5). In addition, cells comprising plexiform
esions of idiopathic PAH are monoclonal in origin (6).
herefore, although the lesions themselves are probably
Abbreviations and Acronyms
BMP  bone morphogenetic proteins
ET  endothelin
5-HT  5-hydroxytryptamine
NO  nitric oxide
PAH  pulmonary arterial hypertension
TGF-  transforming growth factor-beta
TGF-R2  transforming growth factor-beta type-2
receptor
VEGF  vascular endothelial growth factor
VIP  vasoactive intestinal peptideemodynamically irrelevant, they may represent more than fiimply the result of severe elevation of intravascular pres-
ures.
It has been suggested that the endothelial proliferation
een in these lesions may be a marker of a fundamental
ndothelial abnormality in idiopathic PAH, possibly playing
key role in the pathogenesis of the condition. Intriguing
efects in growth suppressive genes have been reported in
lexiform lesions of patients with idiopathic PAH, includ-
ng transforming growth factor-beta (TGF-) receptor-2
nd the apoptosis-related gene, Bax (7). Thus, in approxi-
ately 30% of plexiform lesions there is a somatic frame-
hift mutation in the transforming growth factor-beta
ype-2 receptor (TGF-R2) gene encoding a premature
top codon. Furthermore, in 90% of plexiform lesions the
GF-R2 protein is not expressed, in contrast to the
bundant expression in endothelial cells outside these le-
ions. Thus, it has been proposed that somatic mutations in
rowth regulatory genes allow clonal expansion of endothe-
ial cells, that contribute to the formation of plexiform
esions and vascular obliteration (7). Human herpesvirus-8
nfection may also contribute to the growth of monoclonal
ndothelial cells in plexiform lesions from patients with
diopathic PAH (8). These findings suggest that triggers,
ncluding vasculotropic viruses, can encourage the growth of
ndothelial cells by dysregulating cell growth or growth-
actor signaling.
nflammatory cells. Inflammatory mechanisms appear to
lay a significant role in some types of pulmonary hyper-
ension including monocrotaline-induced cases in rats and
AH of various origins in humans including connective
issue diseases and human immunodeficiency virus infection
9). Interestingly, some patients with severe PAH associated
ith systemic lupus erythematosus have improved with
mmunosuppressive therapy, emphasizing the relevance of
nflammation in this subset of patients (9). Patients with
diopathic PAH also have some immunological disturbances
peaking in favor of a possible role for inflammation in the
athophysiology of this disease. Indeed, a subset of PAH
atients have circulating autoantibodies including antinu-
lear antibodies, as well as elevated circulating levels of
roinflammatory cytokines IL-1 and IL-6. Lung histology
lso revealed inflammatory infiltrates (macrophages and
ymphocytes) in the range of plexiform lesions in severe
AH as well as an increased expression of chemokines
ANTES and fractalkine (10). Further analysis of the role
f inflammatory mechanisms is necessary to understand
hether this component of the disease is relevant to its
athophysiology.
latelets and thrombosis. Thrombotic lesions and platelet
ysfunction are potentially important processes in PAH
11). In situ pulmonary artery thrombosis may be initiated
r aggravated by abnormalities in the clotting cascade, the
ndothelial cells, or the platelets. Biologic evidence shows
hat intravascular coagulation is a continuous process in
AH patients, characterized by elevated plasma levels of
brinopeptide A- and D-dimers. In addition, procoagulant
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June 16, 2004:13S–24S Pathobiology of Pulmonary Arterial Hypertensionctivity and fibrinolytic function of the pulmonary endothe-
ium are altered in PAH. This dysfunction is reflected by
he demonstration of elevated plasma levels of von Wille-
rand factor and plasminogen activator inhibitor type-1. At
he present time, it is widely accepted that the shear stress
tself or injury of the lung vessels generates a thrombogenic
urface with subsequent thrombotic lesions. Thus, it appears
his prothrombotic diathesis is shared by many forms of
ulmonary hypertension, and is not unique to PAH.
Moreover, an increasing body of evidence also suggests
hat enhanced interactions between platelets and the pul-
onary artery wall may contribute to the functional and
tructural alterations of pulmonary vessels. Vascular abnor-
alities in PAH may lead to release by platelets of various
rocoagulant, vasoactive, and mitogenic mediators. Indeed,
n addition to its role in coagulation, the platelet stores and
eleases important contributors to pulmonary vasoconstric-
ion and remodeling such as thromboxane A2, platelet-
ctivating factor, serotonin (5-hydroxytryptamine [5-HT]),
latelet-derived growth factor (PDGF), TGF-, and
EGF. In most cases, however, it remains unclear whether
hrombosis and platelet dysfunction are causes or conse-
igure 1. Consequences of pulmonary artery endothelial cell dysfunction
ulmonary artery endothelial cells (blue) have a decreased production of
romoting vasoconstriction and proliferation of pulmonary artery smooth
uanosine monophosphate; ET  endothelin; ETA  endothelin receptouences of the disease (11). cOLECULAR MECHANISMS
ulmonary vasoconstriction is believed to be an early com-
onent of the pulmonary hypertensive process. Excessive
asoconstriction has been related to abnormal function or
xpression of potassium channels, as well as to endothelial
ysfunction (1,2). Endothelial dysfunction leads to chroni-
ally impaired production of vasodilators such as nitric oxide
NO) and prostacyclin along with prolonged overexpression
f vasoconstrictors such as endothelin (ET)-1, which not
nly affect vascular tone, but also promote vascular remod-
ling and, therefore, represent logical pharmacological tar-
ets (Fig. 1). It appears that most stimuli that acutely
nhance vasoconstriction ultimately also cause cell prolifer-
tion (e.g., K channel inhibition, ET-1).
rostacyclin, vasoactive intestinal peptide, and NO.
rostacyclin (prostaglandin I2) is an important endogenous
ulmonary vasodilator acting through activation of the
yclic adenosine monophosphate (cAMP)-dependent path-
ays. Prostacyclin also inhibits the proliferation of vascular
mooth muscle cells and decreases platelet aggregation.
rostacyclin synthesis is decreased in endothelial cells from
AH patients. Analysis of urinary metabolites of prostacy-
lmonary artery smooth muscle cell tone and proliferation. Dysfunctional
acyclin and nitric oxide, with an increased production of endothelin-1-
e cells (red). cAMP  cyclic adenosine monophosphate; cGMP  cyclic
TB  endothelin receptor B; PDE5  phosphodiesterase type 5.on pu
prost
muscl
r A; Elin showed a decrease in the amount of excreted
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Pathobiology of Pulmonary Arterial Hypertension June 16, 2004:13S–24S-ketoprostaglandin F1, a stable metabolite of prostacy-
lin, in patients with idiopathic PAH (12). Moreover,
ulmonary endothelial cells of PAH patients are character-
zed by reduced expression of prostacyclin synthase (13),
nd prostacyclin therapy has been shown to improve hemo-
ynamics, clinical status, and survival of patients displaying
evere PAH.
Impaired endothelium-derived vasodilation is further sup-
orted by the demonstration of reduced NO synthase expres-
ion in pulmonary endothelial cells from PAH patients (14). A
ovel therapeutic strategy in PAH aims at increasing NO-
ependent, cyclic guanosine monophosphate-mediated pul-
onary vasodilation by inhibition of the breakdown of cyclic
uanosine monophosphate by phosphodiesterase type-5. In a
mall group of PAH patients, sildenafil has been shown to be
afe and effective on a chronic basis (15).
Vasoactive intestinal peptide (VIP), a neuropeptide pri-
arily functioning as a neurotransmitter, acts as a potent
ystemic and pulmonary vasodilator. It also inhibits the
roliferation of vascular smooth muscle cells and decreases
latelet aggregation; VIP acts through two receptor sub-
ypes (VPAC-1 and -2), which are coupled to adenylate
yclase and expressed in the lung vasculature (16). Stimu-
ation of VPAC receptors leads to the activation of the
AMP and cyclic guanosine monophosphate (cGMP) sys-
ems. Low serum concentrations and decreased VIP immu-
oreactivity were shown in pulmonary arteries from patients
ith idiopathic PAH. In addition, higher expression of VIP
eceptors and elevated specific receptor binding activity in
ulmonary artery smooth muscle cells from idiopathic PAH
as demonstrated, which presumably reflects VIP defi-
iency. Acute and chronic responses to inhaled VIP have
een recently demonstrated in a small number of PAH
atients (16).
T-1. Through its action on the endothelin receptor A
ETA) in pulmonary artery smooth muscle cells, ET-1 leads
o a rapid increase in intracellular calcium and sustained
ctivation of protein kinase C. Early activation of the
42/p44 isoforms of mitogen-activated protein kinase and
nduction of the early growth response genes c-fos and c-jun
re also observed (2). The mitogenic action of ET-1 on
ulmonary artery smooth muscle cells occurs through the
TA or endothelin receptor B (ETB) subtype, depending on
he anatomic location of cells. For instance, ETA mediate
itogenesis in cells derived from the main pulmonary
rtery, whereas in cells from resistance arteries both receptor
ubtypes may contribute. There is strong evidence that
ndothelium-derived ET-1 is a major player in the vasodi-
ator/vasoconstrictor imbalance characteristic of PAH. Lev-
ls of lung and circulating ET-1 are increased in animals
nd patients with pulmonary hypertension of various etiol-
gies (17). These observations indicate that ET-1 is likely to
ontribute to the vasoactive component of PAH, as well as
o the abnormal pulmonary vascular remodeling character-
stic of the condition. Results of chronic ET receptor sntagonist therapy support the relevance of this pathway in
AH.
otassium channels. Lessons relevant to PAH can be
earned from understanding the mechanism of hypoxic
ulmonary vasoconstriction, although PAH also involves
ell proliferation and abnormalities of apoptosis (18). Hy-
oxic pulmonary vasoconstriction is elicited when hypoxia
nhibits one or more voltage-gated potassium channels (Kv)
n the pulmonary artery smooth muscle cells of resistance
ulmonary arteries (Fig. 2). The resulting membrane depo-
arization increases the opening of voltage-gated calcium
hannels, raising cytosolic calcium and initiating constric-
ion. The Kv1.5 is downregulated in pulmonary artery
mooth muscle cells in humans with PAH (19), and both
v1.5 and Kv2.1 are downregulated in rats with chronic
ypoxia-induced pulmonary hypertension (20).
Furthermore, deoxyribonucleic acid microarray studies
ave shown downregulation Kv channel genes in PAH
ungs (21). The selective loss of these Kv channels leads to
ulmonary artery smooth muscle cell depolarization, an
ncrease in the intracellular calcium, and both vasoconstric-
ion and cell proliferation. It is not clear whether these Kv
hannel abnormalities are genetically determined or ac-
uired. However, it is clear that the appetite suppressants
exfenfluramine and aminorex directly inhibit Kv1.5 and
v2.1 (22). Augmenting Kv pathways should cause pulmo-
ary vasodilation and promote regression of pulmonary
emodeling. Drugs including dichloroacetate and sildenafil
ay enhance the expression and function of these potassium
hannels. Most of the hemodynamic effects of NO are
ediated by cGMP, which causes vasodilation by activating
rotein kinase G, which phosphorylates and activates BKCA
hannels, as one of several mechanisms by which it lowers
ytosolic calcium.
erotonin. In PAH, circulating serotonin levels are ele-
ated, whereas the level in platelets, the major repository of
igure 2. The balance of tone in pulmonary artery smooth muscle cells.
ctivity of voltage-gated potassium channels (Kv) in the smooth muscle
ells of resistance pulmonary arteries affects vascular tone. In pulmonary
rterial hypertension, the selective loss of Kv channels such as Kv1.5 leads
o pulmonary artery smooth muscle cell depolarization, an increase in the
ntracellular calcium, and both vasoconstriction and cell proliferation.erotonin (5-hydroxytryptamine [5-HT]), is low (23).
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June 16, 2004:13S–24S Pathobiology of Pulmonary Arterial Hypertension-Hydroxytryptamine is produced by the gastrointestinal
ract enterochromaffin cells and pulmonary neuroepithelial
odies and stored in platelets. A role for 5-HT has been
uggested in PAH (23,24). First, a correlation between high
lasma 5-HT levels and PAH was observed in a patient
ith congenital thrombocytopathy characterized by a defect
n the platelet 5-HT storage capacities. Subsequently, ele-
ated plasma 5-HT levels were demonstrated in a series of
AH patients (23). This could not be corrected by lung
ransplantation or epoprostenol therapy, indicating that
aised plasma 5-HT cannot be the mere consequence of
levated pulmonary pressure (23). In the 1960s, an associ-
tion between PAH and the anorexigen aminorex was
dentified. Aminorex induces platelet 5-HT release and
nhibits monoamine oxidase, potentially inhibiting its me-
abolism, thus increasing plasma 5-HT levels. More re-
ently, it was shown that exposure to fenfluramine deriva-
ives increased the risk of developing PAH. By interacting
ith the 5-HT transporter (5-HTT), these anorexigens
elease 5-HT from platelets and inhibit its reuptake and
aise circulating free 5-HT. Additionally, treatment of rats
ith 5-HT potentiates the effects of hypoxia on pulmonary
rterial pressure and remodeling. The mechanism by which
-HT affects the pulmonary vasculature is still a matter of
igure 3. Serotonin receptors and transporter in pulmonary artery smooth m
r both in pulmonary artery smooth muscle cells contribute to pulmonary
rtery smooth muscle cells. A role for other 5-hydroxytryptamine (5-HT)ebate (Fig. 3). hThe 5-HTT expression, activity, or both in pulmonary
rtery smooth muscle cells contribute to the pulmonary
ascular remodeling occurring in both clinical and experi-
ental PAH (24); 5-HTT is encoded by a single gene on
hromosome 17q11.2, and a variant in the upstream pro-
oter region of the 5-HTT gene has been described. This
olymorphism with long (L) and short (S) forms affects
-HTT expression and function with the L-allele inducing
greater rate of 5-HTT gene transcription than the S-allele.
he L-allelic variant was found to be present in homozy-
ous forms in 65% of idiopathic PAH patients but only in
7% of controls (25). Moreover the 5-HTT gene polymor-
hism contributes to interindividual differences in hypoxia-
nduced 5-HTT expression and potentially affects suscepti-
ility to hypoxic pulmonary hypertension (26). Mice
verexpressing the 5-HTT gene exhibit spontaneous pul-
onary hypertension in absence of hypoxia (and exagger-
ted pulmonary hypertension after hypoxic exposure) (27).
inally, recent studies have shown that selective serotonin
euptake inhibitors protect against hypoxic pulmonary hy-
ertension in mice (28).
In human large pulmonary arteries, the 5-HT1 receptor
ediates 5-HT–induced contraction. Further investigation
dentified the 5-HT1B as that mediating contraction in
cells. The 5-hydroxytryptamine transporter (5-HTT) expression, activity,
lar remodeling. The 5-HT1B mediates contraction in human pulmonary
tors such as 5-HT2A and 5-HT2B has also been suggested.uscle
vascu
recepuman small muscular pulmonary arteries (29). In addition,
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Pathobiology of Pulmonary Arterial Hypertension June 16, 2004:13S–24Shere is an increase in the expression of the 5-HT1B receptor
n PAH. Contractile responses to 5-HT in the rat pulmo-
ary circulation are mediated by the 5-HT2A receptor in
ontrol rats, but in chronic hypoxic pulmonary hypertensive
ats the response is increased, and this is mediated by the
-HT1B receptor. Molecular studies confirmed that mes-
enger ribonucleic acid (mRNA) for the 5-HT1B receptor is
ncreased in these vessels. Converging evidence that the
-HT1B receptor may be involved in the development of
ypoxia-induced PAH comes from studies using the
-HT1B/1D antagonist and studies in the 5-HT1B receptor
nockout mouse (30). Development of right ventricular
ypertrophy, and enhanced vasoconstriction to 5-HT1-
eceptor stimulation, is absent in chronic hypoxic pulmo-
ary hypertensive 5-HT1B knockout mice compared with
heir wild-type controls, and pulmonary vascular remodel-
ng is markedly reduced.
A role for other 5-HT receptors such as 5-HT2B has been
uggested. The 5-HT2B receptor is activated by nordexfen-
uramine, the active dexfenfluramine metabolite. Interest-
ngly, development of chronic hypoxic pulmonary hyperten-
ion is ablated in 5-HT2B receptor knockout mice, and the
-HT2B receptor transcript is increased in idiopathic PAH

igure 4. Potential roles of transforming growth factor-beta (TGF-) superf
ariety of physiological processes, including cell proliferation, differentiation, im
nd differentiation factor.atients (31). An interesting link between the K channel hypothesis and the role of serotonin is the finding that K
hannel inhibitors cause serotonin release and inhibit K
urrents in megakaryocytes (32). Moreover, the anorexi-
ens, which inhibit serotonin reuptake and cause serotonin
elease, are K channel blockers (22). This led to the
ypothesis that chronic depolarization of platelets and
ulmonary artery smooth muscle cells could lead to a
asconstricted, pro-proliferative, serotoninemic phenotype.
GF- superfamily. The TGF- superfamily is com-
osed of multifunctional mediators, including the TGF-
soforms (TGF-1–3), the bone morphogenetic proteins
BMPs), activins, and growth and differentiation factors
33,34). The TGF- superfamily has diverse roles in a wide
ariety of physiological processes (Fig. 4). Germline muta-
ions in the gene coding for BMP type-II receptor
BMPR2) have been identified in 60% of familial PAH and
0% to 30% of idiopathic PAH (35–37). The absence of
MPR2 mutations in some families and in the majority of
poradic and associated cases suggests that there may be
urther genes, possibly related to the BMP/TGF- path-
ay, to be identified. Indeed, mutations in the TGF-
eceptors, ALK-1 and endoglin, have been identified in
AH patients with a personal or family history of hereditary
in vascular remodeling. The TGF- superfamily has diverse roles in a wide
ty, and inflammation. BMP bone morphogenetic protein; GDF growthamily
muniemorrhagic telangiectasia (38,39).
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June 16, 2004:13S–24S Pathobiology of Pulmonary Arterial HypertensionThe BMPR-II is a constitutively active serine/threonine
inase receptor, signaling via formation of heterocomplexes
ith one of three type-I receptors (ALK-3/BMPR-IA,
LK-6/BMPR-IB or ALK-2) in response to ligand. The
ain ligands identified for BMPR-II are BMP2, BMP4,
MP7, GDF5, and GDF6. The BMPR-II phosphorylates
glycine-serine–rich domain on the proximal intracellular
ortion of the associated type-I receptor. Activation of the
ype-I receptor kinase domain initiates phosphorylation of
ytoplasmic signaling via the Smad family of proteins. The
MPs signal via a specific set of Smad proteins (Smad1,
mad5, and Smad8) termed “Receptor activated” or
-Smads, which complex with the common partner Smad
r Co-Smad, Smad4, to allow translocation of this signaling
omplex to the nucleus where they can regulate gene
ranscription. However, Smads bind only weakly to DNA
nd require the presence of transcriptional co-activators or
o-repressors.
There are multiple levels at which BMP signaling is
egulated, including the presence of endogenous inhibitors
f BMP-receptor interactions (chordin, noggin, and
AMBI), the formation of specific type-II/type-I receptor
eterocomplexes, the activation of inhibitory Smads (I-
mads, Smad6, and Smad7), and the cell-specific expression
f transcription factors. Such diverse levels of regulation
ay be responsible for the tissue specificity of BMP
ignaling and may, for example, underlie the lung specificity
f PAH. Human pulmonary artery smooth muscle cells and
ndothelial cells express a wide range of TGF- superfamily
eceptors, including BMPR-II and BMPR-IB, and bind
25I-TGF- and 125I-BMP4.
Furthermore, activation of these receptors by BMPs leads
o phosphorylation of Smad1 and induction of mRNAs for
mad6 and Smad7. Although signaling via Smads is well
haracterized, there is increasing evidence that MAP ki-
ases, including ERK, p38MAPK, and JNK kinases, are
ctivated in specific cell types by TGF- and BMPs (33). It
ppears that in some cases the p38 kinase pathway can
ypass the Smad pathway and mediate some of the BMPR2
athway effects on nuclear transcription and apoptosis.
ecent evidence suggests that abnormal activation of alter-
ative signaling pathways may be critical to the pathogen-
sis of PAH (40).
The critical role of the BMP pathway in vascular devel-
pment is evident from studies in knockout mice. Homozy-
osity for a null mutation in BMPR2 is lethal during early
mbryogenesis (41), and mice deficient in Smad5, one of the
MP-restricted Smads, die owing to defects in angiogene-
is, with failure to recruit vascular smooth muscle to
ndothelial structures. The net result of TGF- signaling
n vascular growth and structure is complex. Whether the
GF- superfamily inhibits or promotes cell proliferation is
ighly context-specific.
In situ hybridization and immunohistochemical studies
ave demonstrated that both BMPR-II mRNA and protein
re present predominantly on the pulmonary vascular endo- ihelium, macrophages, and to a lesser extent on medial
mooth muscle cells (42). Lung BMPR-II protein expres-
ion is dramatically reduced in patients harboring an under-
ying BMPR2 mutation predicted to cause truncation of the
rotein (42). In addition, BMPR-II expression is markedly
educed in PAH cases in which no BMPR2 mutation was
dentified (41). A small but significant reduction was also
bserved in cases of secondary pulmonary hypertension.
educed BMPR-II expression was specific for this receptor
ecause no change was observed in the level of expression of
ther endothelial markers, including CD31. These findings
tress the importance of understanding how other environ-
ental and genetic factors regulate the expression of
MPR-II in lung cells. Thus, further characterization of the
egulation of BMPR-II expression is likely to add to our
nderstanding of exogenous factors influencing BMPR-II
ranscription and may provide important clues as to why the
ascular abnormality is restricted to the lung, particularly as
MPR-II is widely expressed in normal adult tissues.
A recently published study has provided further support for
he hypothesis that intact BMP signaling is important for the
aintenance of the normal pulmonary vasculature (43). In this
tudy the type-I receptor BMPR-IA was downregulated in the
ung tissue of a heterogeneous group of patients with pulmo-
ary hypertension. Furthermore, investigators showed a recip-
ocal relationship between BMPR-IA expression and that of
ngiopoietin-1, and they demonstrated that angiopoietin-1
ownregulates BMPR-IA expression in human pulmonary
rtery endothelial cells (43).
Additionally, BMP2, -4, and -7 inhibit the proliferation
f smooth muscle cells derived from normal pulmonary
rteries and from PAH patients with congenital heart
iseases, but they fail to suppress proliferation of cells from
atients with idiopathic or familial PAH (43). An attractive
ypothesis is that a failure of the growth inhibitory effects of
MPs in idiopathic or familial PAH cells could contribute
o the vascular obliteration and remodeling that characterize
he condition. The failure to suppress growth of idiopathic
r familial PAH cells was observed in all cases, whether or
ot specific BMPR2 mutations were identified, suggesting
hat defective BMP-mediated signaling may be a common
actor in idiopathic or familial PAH. The mechanism by
hich BMPR2 mutations disrupt BMPR-II signaling has
egun to be elucidated (Fig. 5) (40,44,45). Interestingly, a
eature common to all mutants is a gain of function
nvolving p38MAPK activation.
In pulmonary artery smooth muscle cells from patients
ith idiopathic PAH, TGF-1 causes enhanced cell pro-
iferation in contrast to the growth inhibitory effect observed
n normal cells (43). This is not due to alterations in
GF-1 receptor ratios or downregulation of TGF-1
ype-II receptor (44). Transforming growth factor-beta is
lso known to increase production of extracellular matrix. In
uman lung fibroblasts, TGF- increases elastin expression
y stabilization of elastin mRNA, and thus it is possible that
ncreased elastin expression observed in PAH may be due to
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ypes have found TGF- to induce collagen production, no
orrelation has been found between procollagen and
GF- staining in lungs of PAH patients (46). The
GF- superfamily may regulate the activity of other
actors implicated in vascular remodeling. The TGF-1
nduces ET-1 in human pulmonary artery cells probably via
ctivation of protein kinase A (47). Connective tissue
rowth factor production can also be stimulated by TGF-
n pulmonary fibroblasts (48). Clearly much remains to be
earned of the interaction of the TGF-/BMP pathway
ith other factors already demonstrated to play important
oles in the control of vascular tone and growth.
ngiogenesis and apoptosis. Vascular endothelial growth
actor is an endothelial-cell-specific-angiogenic mitogen
cting via two high-affinity tyrosine kinase receptors
VEGFR-1 and VEGFR-2). Although the physiological
igure 5. Consequences of bone morphogenetic protein type-II receptor
MPR2 mutations occur within exon 1 of the gene and would be predict
xpress the mutant protein, resulting in haploinsufficiency. Although this fi
utations involving the ligand binding or kinase domain of BMPR-II could
he mechanism by which BMPR-II mutants disrupt BMP/Smad signaling
ithin the ligand binding or kinase domain of BMPR-II leads to failure o
ild-type receptor trafficking. In contrast, noncysteine mutations within t
uciferase reporter gene. Interestingly, BMPR-II mutants with missense m
apable of activating the Smad-responsive luciferase reporter gene. Howeve
as ligand-independent activation of p38MAPK and enhanced serum-indu
educed cell-surface expression of BMPR-II favors activation of p38MA
ignaling in a mutation-specific manner. Thus, a feature common to all mole of the abundantly expressed VEGF in the lung is (nknown, it has been proposed that VEGF supports pul-
onary endothelial cell maintenance and survival. In PAH,
he VEGF expression is increased within the pulmonary
asculature, including the plexiform lesions (5,49). Al-
hough the isoform VEGF-A has been most extensively
tudied in the context of pulmonary hypertension and has
een proposed to play a protective role, a recent study
dentified a pathogenic role for VEGF-B.
In contrast to VEGF-A, the VEGF-B appears to exacer-
ate remodeling as VEGF-B knockout mice (VEGF-B/)
xposed to chronic hypoxia exhibit significantly less pulmonary
ascular remodeling compared with wild-type mice (VEGF-
/) (50). Recent animal studies have emphasized the posi-
ive effects of VEGF in models of pulmonary hypertension
51). Indeed, cell-based VEGF gene transfer has proved an
ffective method of preventing the development and progres-
ion of pulmonary hypertension in the monocrotaline model
R2) mutations on signaling. Mutation analysis demonstrated that some
cause nonsense-mediated messenger ribonucleic acid decay and failure to
may be true for some mutations, it was also found in transfected cells that
t a dominant negative effect on BMPR-II signaling via the Smad pathway.
terogeneous, and mutation specific. Thus, substitution of cysteine residues
cking of the mutant protein to the cell surface, which may interfere with
nase domain reach the cell surface but fail to activate a Smad-responsive
ions involving the cytoplasmic tail reached the cell surface but were still
ature common to all mutants transfected into normal mouse epithelial cells
oliferation. Based on the results of these studies it was hypothesized that
ependent pro-proliferative pathways, while inhibiting Smad-dependent
s is a gain of function involving p38MAPK activation.(BMP
ed to
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r by inducing the development of new blood vessels within
he lung (51).
In idiopathic PAH, VEGFR-1 expression is increased,
hereas within the plexiform lesions it is VEGFR-2 that is
xpressed (52). In rats, it has been shown that the combi-
ation of chronic blockade of VEGFR-2 and chronic
ypoxia could cause pulmonary endothelial cell dysfunction
nd cell death, allowing the selection of an apoptosis-
esistant proliferating endothelial cell phenotype and the
ubsequent development of severe pulmonary hypertension
53). Because endothelial cell death, cell proliferation, and
he development of severe pulmonary hypertension could be
locked by a broad-spectrum caspase inhibitor, it appeared
hat the selection of an apoptosis-resistant endothelial cell
henotype might be the critical event responsible for pul-
onary artery endothelial cell proliferation (53). Therefore,
poptosis of endothelial cells may underlie the propensity to
ascular disease (53).
Various other growth factors including PDGF, basic
broblast growth factor, insulin-like growth factor-1, and
pidermal growth factor have also been implicated in the
evelopment of remodeling and all have been reported to be
ncreased in the pulmonary hypertensive lung. The mecha-
igure 6. Schematic view of pulmonary arterial hypertension (PAH) patho
nd it is unlikely that one factor or gene mutation will explain all forms aism that leads to induction of these growth factors in the dulmonary vasculature is unclear, though reactive oxygen
pecies have been implicated because hydrogen peroxide
nduces PDGF expression in human pulmonary endothelial
ells, as does hypoxia and mechanical stretch and shear
tress.
Angiopoietin-1 is an angiogenic factor essential for lung
ascular development (43). Produced by smooth-muscle cells
nd precursor pericytes, angiopoietin-1 stabilizes the develop-
ent of blood vessels by recruiting muscle cells, through
igration and division, to endothelial tubes, creating mature
rterial structures. The receptor for angiopoietin-1, TIE2, is
resent only on vascular endothelium. The ligand-receptor
nteraction between angiopoietin-1 secreted by smooth-muscle
ells and endothelium-specific TIE2 during organ develop-
ent induces the proliferation of muscle cells around the
ndothelium vascular network.
After development is completed, angiopoietin-1 is ex-
ressed at a minimally detectable level in the human lung.
ecent studies attempted to analyze the putative role of
ngiopoietin-1 in pulmonary hypertension, but they reached
ntirely antithetical conclusions (43,54,55). The findings by
u and colleagues (43) suggest that all forms of nonfamilial
ulmonary hypertension are characterized by upregulation
f angiopoietin-1 and phosphorylated TIE2, correlating
iology. Pulmonary arterial hypertension has a multifactorial pathobiology,
ses of PAH.phys
nd cairectly with the severity of the disease. A mechanistic link
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Pathobiology of Pulmonary Arterial Hypertension June 16, 2004:13S–24Setween familial PAH and acquired pulmonary hyperten-
ion was supported by the finding that angiopoietin-1 shuts
ff the expression of BMPR1A, a transmembrane protein
equired for BMPR2 signaling, in pulmonary arteriolar
ndothelial cells (43). Interestingly, rodents engineered to
xpress angiopoietin-1 in the lung develop pulmonary hy-
ertension (54). These animals manifest diffuse medial
hickening in small pulmonary vessels, resulting from
mooth muscle cell hyperplasia.
In addition, angiopoietin-1 stimulates pulmonary arteriolar
ndothelial cells through a TIE2 pathway to produce and
ecrete 5-HT (54). These revelations suggest that pulmonary
ypertensive vasculopathy occurs through an angiopoietin-1/
IE2/5-HT paracrine pathway and imply that these signaling
olecules may be targets for strategies to treat this disease.
By contrast, Zhao et al. (55) have demonstrated that
ngiopoetin-1 may have a protective role in at least some forms
f pulmonary hypertension. In their study, cell-based gene
ransfer with angiopoietin-1 improved survival and pulmonary
emodynamics in monocrotaline-exposed rats by a mechanism
nvolving the inhibition of apoptosis and protection of the
ulmonary microvasculature (55). These two approaches of the
ole of angiopoietin-1 in PAH reflect distinct views on the
echanisms leading to the disease. On the one hand, the
nvestigators assume that the primary cellular defect contrib-
ting to the disease is smooth muscle cell hyperplasia, and that
his is mediated by excess angiopoietin-1. On the other hand,
t is hypothesized that endothelial apoptosis underlies disease
rogression, and that this can be prevented by administration
f angiopoietin-1. At the present time one cannot conclude
hether angiopoietin-1 is the cause or the cure of PAH, but
ore data are required to evaluate the angiopoietin-1/TIE2
athway in this condition (56).
roteolysis. Evidence that proteolysis of the extracellular
atrix may be important in the pathobiology of pulmonary
ascular disease came from observations of degradation of
lastin in pulmonary arteries from patients with a congenital
eart defect and pulmonary vascular disease (57). These
tudies were supported by work in a variety of rat models of
ulmonary hypertension (hypoxia, monocrotaline) in which
eightened activity of elastase in the pulmonary arteries was
ocumented as a very early feature after the injurious
timulus (57). Subsequent studies showed that infusion of
lastase inhibitors suppressed the disease process (58,59). It
as then shown that serum factors could induce the
roduction of an endogenous vascular elastase from smooth
uscle cells and that the mechanism appeared to involve
AP kinase activity and nuclear partitioning of the tran-
cription factor AML1 (60). This is a transcription factor
or neutrophil elastase and a putative transcription factor for
ndogenous vascular elastase, based on studies using anti-
ense blockade of AML1 to repress elastase activity.
Moreover, repression of nuclear partitioning of AML1 as
ell as repression of phosphorylation of Erk (a member of
he MAP kinase family) was achieved with NO donors, and
his also repressed elastase activity (61). Suppression of-HT receptors repressed elastase activity and TGF- in
hronic hypoxia. Also, to be further investigated is the
elationship between BMPR-II and the induction of elas-
ase activity. Hypothetically, it has been proposed that
MPR-II induces Smadl/5 interaction with AML1, thus
reventing its interaction with Smad4 and repressing its
bility to partner with other transcription factors and to
nduce elastase activity. Conversely, a mutation in
MPR-II would result in derepression of AML1 and
nduction of elastase and other AML1-dependent genes.
Evidence from the published data indicates that serine
lastases activate MMPs and also repress tissue inhibitors of
MPs. In other injury models, elastase activity has been
hown to precede MMP activity and is responsible for its
nduction. In the monocrotaline model, an elevation in
lastase activity is seen on day 2 after injection of the toxin,
hereas MMP activity is not increased until day 21. Both
MPs and elastases can degrade most components of the
atrix in addition to elastin and collagen. Degradation of
ollagen leads to ligation of 3 integrins activation of the
AP kinase pathway and transcription of tenascin C. This
lycoprotein cooperatively interacts with growth factors
uch as epidermal growth factor in inducing smooth muscle
ell proliferation. Repression of this pathway by elastase
nhibitors has been shown in cell and organ culture and in
hole animals to induce apoptosis of smooth muscle cells,
nd regression of severe vascular disease (58,59).
onclusions. It is clear that PAH has a multifactorial
athobiology, and it is unlikely that one factor or gene
utation will explain all forms and cases of PAH (Fig. 6).
owever, the current understanding of the mechanisms
nderlying PAH has allowed the rapid development of
rugs including prostacyclin, endothelin receptor antago-
ists, and phosphodiesterase inhibitors. Our improved un-
erstanding of additional pathways in this condition will
resumably lead to the development of novel therapeutic
trategies in the near future, such as ion channel replace-
ent therapy or cell-based therapies, using bone marrow
recursor cells.
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